Skip to main content

Mineralys Therapeutics, Inc.

MLYS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001933414

In the last 90 days, Mineralys Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 225 institutions reported holding it in 13F filings for Q2 2026, worth $2.69B in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Mineralys Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of MLYS: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders9294+2
Shares41.9M44.2M+2.28M (+5.4%)
Value$540.6M$516.6M−$24.0M (−4.4%)

New holders (14)

Institutions that held Mineralys Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to MLYS in Q2 2024
InstitutionSharesValue% of portfolio
Caligan Partners LP745,758$8.73M2.04%
Jennison Associates LLC683,257$7.99M0.01%
Boothbay Fund Management, LLC424,183$4.96M0.16%
Prudential Financial Inc67,650$791.5K0.00%
Verition Fund Management LLC20,953$245.2K0.00%
Corebridge Financial, Inc.15,362$179.7K0.00%
Manufacturers Life Insurance Company, The12,432$145.5K0.00%
Mirae Asset Global ETFs Holdings Ltd.9,762$114.2K0.00%
Mirae Asset Global Investments Co., Ltd.1,482$17.0K0.00%
Smartleaf Asset Management LLC357$4.11K0.00%
Allworth Financial LP133$1.76K0.00%
SRS Capital Advisors, Inc.108$1.26K0.00%
Advisor Group Holdings, Inc.100$1.17K0.00%
Rothschild Investment LLC20$2340.00%

Sold out (12)

Institutions that held Mineralys Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.